In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sloan-Kettering Institute

Division of Memorial Sloan Kettering Cancer Center

Latest From Sloan-Kettering Institute

Siamab, BI Team To ‘Attack’ Potential Of Carbohydrate Antibodies In Cancer

With promising preclinical data for lead candidate ST1 in ovarian cancer, Siamab thinks therapeutics targeting tumor-associated carbohydrate antigens will offer potential in multiple solid tumor types.

Deals Platform Technologies

Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position

Juno and partner Celgene closed the ROCKET study for JCAR015, which has been on clinical hold since November, and ended development in ALL in favor of its new and improved CD19-targeting CAR-T therapies.

Cancer Companies

Making The Grade? Big Pharma Deals With Academia Begin To Score

With three to four years in the books, Big Pharma’s updated tie-ups with academia have started to progress – some have even reached first-in-human stages, but these updated models have yet to produce any radical results that show they are an improvement over old-style partnerships.

BioPharmaceutical Strategy

Aton Pharma Inc.

Over the course of two decades, three leading cancer investigators from Memorial Sloan-Kettering Cancer Center (MSKCC), Paul Marks, MD, Richard Rifkind, MD, and Victoria Richon, PhD, along with Ronald Breslow, PhD of Columbia University, have performed research with the objective to develop safer, more effective cancer treatments. Their pioneering work focused on an emerging class of anti-tumor agents-histone deacetylase (HDAC) inhibitors. Now the team of four hopes to translate lab research to drug development in Aton Pharma Inc.
BioPharmaceutical Clinical Trials
See All